Up-titration to high-intensity statins early on in the course of treatment was found to be associated with a lower risk for cardiovascular (CV) events compared with no up-titration in patients at very high risk for CV disease.
Alirocumab was found to be well tolerated and to produce long-term reductions in low-density lipoprotein cholesterol in patients who are intolerant to statins.
Hypertension and dyslipidemia display a correlation with rosacea, although ischemic heart disease, stroke, and diabetes do not.
The majority of patients with acute coronary syndrome treated with statins were found to have low-density lipoproteins-cholesterol levels above those recommended by current guidelines.
Coenzyme Q10 supplementation was not found to improve statin therapy adherence or relieve associated muscle pain in patients with statin-associated myalgia.
The management of cardiovascular risk in patients with diabetes admitted with COVID-19 should be adapted to this population.
A novel study assesses the safety and efficacy of apremilast in patients with psoriasis and evaluates the treatment as a metabolic modulator.
Treatment with statins was found to reduce the risk for disease recurrence in patients with venous thromboembolism.
Obesity may be associated with a greater risk for pulmonary hypertension.
Phenylacetylglutamine (PAGln), a metabolite derived from gut microbiota, may contribute to cardiovascular disease (CVD) and thrombosis.
